Opinion|Videos|August 8, 2024 (Updated: July 23, 2024)
Managing ILD and Pneumonitis Risk From ADCs
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the most common toxicities associated with ADCs? Which are most concerning for physicians? For patients?
- What toxicities are of greatest concern for patients withgynecologic, GI, Lung ,and GU cancers?
Advertisement
Related to this article
The FDA approved rusfertide for the treatment of patients with polycythemia vera.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
Sequencing, Access, and Eligibility Drive CAR T-Cell Therapy Decisions in Early Relapse Myeloma
3
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
4
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
5